CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1438 participants.
Also called NCT04136171
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,438 participants
- Registry
-
NCT04136171 -
2019-002835-27 -
2024-514434-20-00
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, Poland, Portugal, Puerto Rico, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04136171. Randomized; double masking; primary purpose treatment. Start 2020-03-13 (actual); primary completion 2026-03-25 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
- Condition
- Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
- Intervention (Drug)
- Eplontersen
- Intervention (Drug)
- Placebo
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct04136171- Content hash
fb6bec089cb27892e68031367fceb745bb707be854f1f8407635075cce69509c